• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Imunon Inc.

    11/14/24 12:17:50 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMNN alert in real time by email
    SC 13G/A 1 tm2428264d3_sc13ga.htm SC 13G/A

     

     

     

    CUSIP No: 15117N602

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. 1)*

     

    Imunon, Inc.

    (Name of Issuer)

     

    Common Stock, $0.01 par value per share

    (Title of Class of Securities)

     

    15117N602
    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

     ¨ Rule 13d-1(b)
     x Rule 13d-1(c)
     ¨ Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No: 15117N602

     

    (1) NAMES OF REPORTING PERSONS
       
      CVI Investments, Inc.
    (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
      (a) ¨
        (b) ¨
       
    (3) SEC USE ONLY
       
    (4) CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Cayman Islands

     
    NUMBER OF (5) SOLE VOTING POWER
       
    SHARES 0
       
    BENEFICIALLY (6) SHARED VOTING POWER **
       
    OWNED BY 761,587
       
    EACH (7) SOLE DISPOSITIVE POWER
       
    REPORTING   0
       
    PERSON WITH (8) SHARED DISPOSITIVE POWER **
       
      761,587

    (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      761,587
    (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
                 ¨
       
    (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
      4.9%
    (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      CO

     

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

    CUSIP No: 15117N602

     

    (1) NAMES OF REPORTING PERSONS
       
      Heights Capital Management, Inc.
    (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
      (a) ¨
        (b) ¨
       
    (3) SEC USE ONLY
       
    (4) CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Delaware

     
    NUMBER OF (5) SOLE VOTING POWER
       
    SHARES 0
       
    BENEFICIALLY (6) SHARED VOTING POWER **
       
    OWNED BY 761,587
       
    EACH (7) SOLE DISPOSITIVE POWER
       
    REPORTING   0
       
    PERSON WITH (8) SHARED DISPOSITIVE POWER **
       
      761,587

    (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      761,587
    (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
                 ¨
       
    (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
      4.9%
    (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      CO

     

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: 15117N602

      

    Item 1.

     

    (a) Name of Issuer

     

    Imunon, Inc. (the “Company”)

     

    (b) Address of Issuer’s Principal Executive Offices

     

    997 Lenox Drive, Suite 100, Lawrenceville, NJ 08648

     

    Item 2(a). Name of Person Filing

     

    This statement is filed by the entities listed below, who are collectively referred to herein as “Reporting Persons,” with respect to the shares of common stock of the Company, $0.01 par value per share (the “Shares”).

     

    (i)CVI Investments, Inc.

     

    (ii)Heights Capital Management, Inc.

      

    Item 2(b). Address of Principal Business Office or, if none, Residence

     

    The address of the principal business office of CVI Investments, Inc. is:

     

    P.O. Box 309GT

    Ugland House

    South Church Street

    George Town

    Grand Cayman

    KY1-1104

    Cayman Islands

     

    The address of the principal business office of Heights Capital Management, Inc. is:

     

    101 California Street, Suite 3250

    San Francisco, California 94111

     

    Item 2(c). Citizenship

     

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d) Title of Class of Securities

     

    Common stock, $0.01 par value per share

     

    Item 2(e) CUSIP Number

     

    15117N602

     

     

     

     

    CUSIP No: 15117N602

      

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
     
    (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
     
    (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
     
    (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
     
    (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
    (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
    (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
    (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
    (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
    (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
    (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ________________

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    The number of Shares reported as beneficially owned consists of Shares issuable upon the exercise of warrants to purchase Shares (the “Warrants”). The Warrants are not exercisable to the extent that the total number of Shares then beneficially owned by a Reporting Person and its affiliates and any other persons whose beneficial ownership of Shares would be aggregated with such Reporting Person for purposes of Section 13(d) of the Exchange Act, would exceed 4.99%.

     

    The Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2024 indicates there were 14,500,685 Shares outstanding as of September 30, 2024.

     

    Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     

    1

     

     

    CUSIP No: 15117N602

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7.         Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    CUSIP No: 15117N602

     

    SIGNATURES

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

     

    Dated: November 12, 2024

     

    CVI INVESTMENTS, INC.   HEIGHTS CAPITAL MANAGEMENT, INC.
         
    By: Heights Capital Management, Inc.   By: /s/ Brian Sopinsky
    pursuant to a Limited Power of Attorney, a copy of which was previously filed   Name:
    Title:
    Brian Sopinsky
    Secretary
         
    By: /s/ Brian Sopinsky    
    Name: Brian Sopinsky    
    Title: Secretary      

     

     

     

     

    CUSIP No: 15117N602

     

    EXHIBIT INDEX

     

    EXHIBIT   DESCRIPTION
    I   Limited Power of Attorney*
    II   Joint Filing Agreement*

     

    *Previously filed

     

     

    Get the next $IMNN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMNN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IMNN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19

      Company's PlaCCine® technology platform demonstrates better durability and other advantages compared to mRNA vaccines Results further validate PlaCCine as a novel vaccine platform with potential applications in COVID-19 and other infectious diseases with epidemic implications LAWRENCEVILLE, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company focused on developing non-viral DNA-mediated immunotherapies and evaluating an adaptation of the platform's potential as a next-generation vaccine, today announced new data from its first Phase 1 proof-of-concept clinical trial of IMNN-101, an investigational DNA plasmid vaccine based on the Company's proprieta

      5/15/25 8:05:00 AM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update

      First site initiated for Phase 3 OVATION 3 study of IMNN-001 in treatment of newly diagnosed advanced ovarian cancer New data from Phase 2 OVATION 2 study of IMNN-001 accepted for oral presentation at 2025 ASCO Annual Meeting Company to hold conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today reported financial results for the three months ended March 31, 2025 and highlighted recent business updates, including progress in advancing Phase 3 clinical development of its lead candidate IMNN-001 in newly diagnosed advanced ovarian can

      5/12/25 8:00:00 AM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

      Company currently initiating additional trial sites and working with study investigators to enroll participants IMNN-001 is the first and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in women with advanced ovarian cancer Data from Phase 2 OVATION 2 Study are encouraging, with new IMNN-001 data to be highlighted in oral presentation at 2025 ASCO Annual Meeting LAWRENCEVILLE, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the first trial site has been initiated for the Company's Phase 3 pivotal study, called OVATION 3, of its le

      5/8/25 8:05:00 AM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMNN
    Leadership Updates

    Live Leadership Updates

    See more
    • IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer

      Dr. Faller joins IMUNON with more than 30 years of industry, academic and laboratory experience, with specialized expertise in oncology and immunology LAWRENCEVILLE, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced the appointment of Douglas V. Faller, M.D., Ph.D., as chief medical officer, effective February 18, 2025. In this role, Dr. Faller will lead the company's clinical strategy including advancing its lead program IMNN-001 for the treatment of newly diagnosed advanced ovarian cancer, which is on track to enter a Phase 3 pivotal trial in the first quarter of 202

      2/10/25 8:05:00 AM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO

      Assumes leadership role as Company anticipates multiple near-term clinical milestones Brings extensive leadership and experience in drug development and business strategy LAWRENCEVILLE, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, today announced the appointment of Stacy R. Lindborg, Ph.D. as President and Chief Executive Officer, effective May 13, 2024. Dr. Lindborg has served on IMUNON's board of directors since 2021. Dr. Lindborg assumes the leadership of IMUNON at a pivotal time. Topline results from the Phase 2 OVATION 2 Stud

      5/8/24 8:00:00 AM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      Accomplished pharmaceutical and biotechnology executive to lead IMUNON's clinical programs in ovarian cancer and infectious diseases LAWRENCEVILLE, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces the appointment of Sebastien Hazard, M.D. as Chief Medical Officer, effective December 11, 2023. Dr. Hazard brings to IMUNON a strong background in building and leading clinical development organizations, most recently at Bicycle Therapeutics. He will report to IMUNON's President and Chief Executive Officer, Dr. Corinne Le

      12/11/23 8:30:00 AM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMNN
    SEC Filings

    See more
    • Imunon Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Imunon, Inc. (0000749647) (Filer)

      5/20/25 7:00:28 AM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form S-1/A filed by Imunon Inc.

      S-1/A - Imunon, Inc. (0000749647) (Filer)

      5/19/25 8:20:49 AM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form S-1/A filed by Imunon Inc.

      S-1/A - Imunon, Inc. (0000749647) (Filer)

      5/13/25 6:10:57 AM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMNN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Braun Donald P bought $29,480 worth of shares (25,000 units at $1.18), increasing direct ownership by 4,188% to 25,597 units (SEC Form 4)

      4 - Imunon, Inc. (0000749647) (Issuer)

      1/28/25 4:18:24 PM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Lindborg Stacy bought $24,500 worth of Imunon Common Stock (25,000 units at $0.98), increasing direct ownership by 10% to 264,166 units (SEC Form 4)

      4 - Imunon, Inc. (0000749647) (Issuer)

      8/16/24 8:03:50 AM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Executive Chairman of Board Tardugno Michael H bought $25,750 worth of Imunon Common Stock (25,000 units at $1.03), increasing direct ownership by 8% to 353,346 units (SEC Form 4)

      4 - Imunon, Inc. (0000749647) (Issuer)

      8/16/24 8:01:30 AM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMNN
    Financials

    Live finance-specific insights

    See more
    • IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update

      First site initiated for Phase 3 OVATION 3 study of IMNN-001 in treatment of newly diagnosed advanced ovarian cancer New data from Phase 2 OVATION 2 study of IMNN-001 accepted for oral presentation at 2025 ASCO Annual Meeting Company to hold conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today reported financial results for the three months ended March 31, 2025 and highlighted recent business updates, including progress in advancing Phase 3 clinical development of its lead candidate IMNN-001 in newly diagnosed advanced ovarian can

      5/12/25 8:00:00 AM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025

      LAWRENCEVILLE, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company will host a conference call at 11:00 a.m. ET on Monday, May 12, 2025 to discuss financial results for the first quarter ended March 31, 2025 and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy, including progress in advancing the IMNN-001 development program toward initiation of a Phase 3 clinical trial in advanced ovarian cancer. To participate in the call, interested parties may dial 833-816-1132 (Toll-Free/North America) or

      5/5/25 8:00:00 AM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

      First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer Initiation of trial sites underway for ground-breaking Phase 3 pivotal trial of DNA-mediated IL-12 therapeutic Company to hold conference call on Tuesday, March 25, 2025, at 2:00 p.m. ET LAWRENCEVILLE, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) is aligned with the protocol for the Phase 3 pivotal trial, called OVATION 3, of its lead candidate IMNN-001 in development for the treatment

      3/24/25 8:00:00 AM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMNN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Imunon Inc.

      SC 13G - Imunon, Inc. (0000749647) (Subject)

      11/14/24 5:37:34 PM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Imunon Inc.

      SC 13G/A - Imunon, Inc. (0000749647) (Subject)

      11/14/24 12:17:50 PM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Imunon Inc.

      SC 13G - Imunon, Inc. (0000749647) (Subject)

      8/5/24 11:53:32 AM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Scientific Officer Anwer Khursheed

      4 - Imunon, Inc. (0000749647) (Issuer)

      3/18/25 4:23:13 PM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Fritz Frederick J.

      4 - Imunon, Inc. (0000749647) (Issuer)

      3/18/25 4:22:09 PM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Braun Donald P

      4 - Imunon, Inc. (0000749647) (Issuer)

      3/18/25 4:21:11 PM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care